Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Proline rich 14-like protein (PRR14L) is a large, evolutionarily conserved protein that contains a C-terminal Tantalus domain, which includes a protein phosphatase 2A (PP2A) binding motif, and shares this domain with its paralog PRR14[1][5]. PRR14L localizes to the midbody during cell division and is thought to act as a scaffold for PP2A, influencing cell division and hematopoietic differentiation[5]. PRR14L mutations are associated with certain myeloid neoplasms and age-related clonal hematopoiesis, with functional studies suggesting tumor suppressor-like activity whereby loss leads to increased monocytes and decreased granulocytes[5]. Unlike PRR14, PRR14L is not involved in nuclear lamina/heterochromatin tethering or chromatin organization, and its full spectrum of biological functions is still under investigation[1][5]. Currently, it is not considered a therapeutic target, no interacting drugs have been identified, and no biomarker or safety data exists regarding therapeutic modulation of PRR14L.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Proline rich 14-like protein (PRR14L).